News-Medical.net FACTIVE® is an FDA-approved quinolone with 5-day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia. Pursuant to definitive agreements, Okana acquired ...
Family Practice News Digital Network According to the FDA, 23 million outpatients were prescribed an oral quinolone in 2011. A total of 70% received ciprofloxacin; 28% were prescribed levofloxacin; and 9% were given moxifloxacin. Gemifloxacin, ofloxacin, and norfloxacin each accounted for ... and more »
pharmabiz.com This uniquely designed drug, utilizing a fourth generation quinolone therapy combined with potent inflammatory suppression, when placed as a depot inside the vitreous concurrent with cataract surgery, or any intraocular procedure, addresses the primary ...
Canada NewsWire (press release) FACTIVE® is an FDA-approved quinolone with 5-day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia. Pursuant to definitive agreements, Okana acquired ... and more »
